SEARCH

SEARCH BY CITATION

References

  • 1
    Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14: 158994.
  • 2
    Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17–22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 3741.
  • 3
    Tolman KG, Chandramouli J, Fang JC. Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2000; 1: 117194.
  • 4
    Van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2000.
  • 5
    Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomised clinical trials. Clin Ther 2001; 23: 9981017.
  • 6
    Tytgat GN. Review article: long-term use of proton pump inhibitors in GERD — help or hindrance? Aliment Pharmacol Ther 2001; 15(Suppl. 2): 69.
  • 7
    Myrvold HE, Lundell L, Miettinen P, et al. The cost of long-term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 2001; 49: 48894.
  • 8
    Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 107989.
  • 9
    Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group [published erratum appears in Aliment Pharmacol Ther 1999; 13: 567]. Aliment Pharmacol Ther 1999; 13: 49–57.
  • 10
    Thjodleifsson B, Beker JA, Dekkers CP, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45: 84553.
  • 11
    Lanza F, Bardhan KD, Perdomo C, et al. Efficacy of rabeprazole once daily for acid-related disorders. Dig Dis Sci 2001; 46: 58796.
  • 12
    Thjodleifsson B, Cockburn I. Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther 1999; 13(Suppl. 5): 1723.
  • 13
    Geboes K, Dekker W, Mulder CJ, et al. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001; 15: 181926.
  • 14
    Bardhan KD, Cherian P, Bishop AE, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 2001; 96: 176776.
    Direct Link:
  • 15
    Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 6619.
  • 16
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 90312.
  • 17
    Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 116181.
  • 18
    Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185200.
  • 19
    Bardhan KD, Cherian P, Vaishnavi A, et al. Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo. Gut 1998; 43: 45864.
  • 20
    Ladas SD, Tassios PS, Raptis S. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring. Am J Gastroenterol 2000; 95: 37480.
  • 21
    McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 1997; 9: 11617.
  • 22
    Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 85763.
  • 23
    Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.
  • 24
    Sagar M, Bertilsson L, Stridsberg M, et al. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I and chromogranin A in patients with acid-related disorders. Aliment Pharmacol Ther 2000; 14: 1495502.
  • 25
    Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001; 13: S437.
  • 26
    McGuigan JE. Zollinger–Ellision syndrome and other hypersecretory states. In: FeldmanM, ScharschmidtBF, SleisengerMH, KleinS, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease Pathophysiology/Diagnosis/Management, 6th edn. Philadelphia: W. B. Saunders, 1998: 67995.
  • 27
    Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000; 14: 1522.
  • 28
    Yeomans ND, Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 2000; 14: 26771.
  • 29
    Nakshabendi IM, Zhang QB, Mokhashi M, et al. Effect of omeprazole therapy on the survival of Helicobacter pylori, urease activity, and antral gastric histology in patients with duodenal ulcer. Helicobacter 1996; 1: 1558.
  • 30
    Tsutsui N, Taneike I, Ohara T, et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the mobility of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 306973.
  • 31
    Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 5262.
  • 32
    Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6: S491505.
  • 33
    Byrne MF, Murray FE. Formulary management of proton pump inhibitors. Pharmacoeconomics 1999; 16: 22546.